skip to Main Content

KRAS G12C Inhibitor Sotorasib Shows Activity in Certain Patients With Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Sotorasib, an irreversible inhibitor of KRAS G12C, showed activity in patients with metastatic pancreatic cancer and a KRAS G21C mutation enrolled in the phase I/II CodeBreaK100 study. These findings were presented during the February 2022 ASCO Plenary Series session by John H. Strickler, MD, Associate Professor of Medicine at Duke University Medical Center

Treatment with sotorasib was associated with a centrally confirmed objective response rate of 21.1% and a disease control rate of 84.3% in heavily pretreated patients, demonstrating “clinically meaningful activity” in the largest data set yet to evaluate the efficacy and safety of a KRAS G12C inhibitor in pancreatic cancer, Dr. Strickler said.   Read more . . . 


Back To Top